As planning, guiding and assessing Liver Cancer interventions may be challenging, GE has developed a Complete Suite of Comprehensive Solutions to enable Excellence in both Liver Care endovascular and percutaneous procedures with Cone Beam CT.
Liver cancer accounts for approximately 64%1 of all Interventional Oncology procedures and Cone Beam CT is proven to improve the feasibility, effectiveness, and safety of challenging interventions.2 GE’s comprehensive Liver Care solutions are engineered to enable physicians to access the full potential of Cone Beam CT images within their daily practice by removing the most common barriers that stand along the course of their minimally invasive liver treatment.
From acquisition to application, through final assessment, GE's complete Liver Care portfolio supports excellence in endovascular and percutaneous procedures by enabling:
High-quality Cone Beam CT acquisitions with Discovery IGS 73 (wide bore gantry, 41 cm2 detector).
Compensation for involuntary respiratory motion artifacts that threaten Cone Beam CT quality with exclusive Motion Freeze solution.4
Precise planning and embolization guidance with Liver ASSIST.5 Liver ASSIST provides a high sensitivity in detecting liver tumor feeding vessels. It improves the sensitivity of tumor-feeding vessels identification to reach up to 97-percent.11, 12, 13 It has demonstrated ~68% complete tumor response rate (vs. 36% with DSA alone)14
Automatic fusion between ultrasound7 and Cone Beam CT as well as other pre-operative images using INTERACT Active Tracker.6
Real-time visualization of needle positions in the 3D space with Needle ASSIST to help you improve your accuracy, reduce dose and support efficiency efforts when performing needle interventions8 in the angio suite.
The combined capabilities of GE's Liver Care portfolio equip clinical teams to confidently access and leverage Cone Beam CT in even the most challenging procedures for endovascular and needle-based treatments.
Feature Item1
64% of IO procedures are targeting the Liver.1
GE solutions address endovascular & ablative care with diversified solutions.
Feature Item 2
GE Liver Care portfolio allows 3D imaging to potentially more than 95% of the world’s adult population (aged 15 to 100)9 thanks to the Discovery IGS 7, one of the widest bore on the market today.
Feature Item 3
Physicians estimate that up to 40%10 of Cone Beam CT acquisitions are unusable due to involuntary respiratory motion artifacts. Motion Freeze can help salvage Cone Beam CT acquisitions by refining and increasing small contrasted structures in Cone Beam CT images.4
Feature Item 4
Liver ASSIST is the only software solution able to demonstrate ~68% complete tumor response rate (vs. 36% with DSA alone).14
Discovery IGS 7 wide bore allows to perform uninterrupted 3D. It also provides an easy centering of the liver even for patients with arms down. Its industry largest 41 x 41 cm detector enables large anatomies coverage.
The pioneering Motion Freeze solution4a makes a difference by compensating for involuntary respiratory motion on your Cone Beam CT and thus saving up to 25% of repeated Cone Beam CT.10
Liver ASSIST provides a high sensitivity in detecting liver tumor feeding vessels. It improves the sensitivity of tumor-feeding vessels identification to reach up to 97-percent.11, 12, 13
Liver ASSIST5 is the only software solution able to demonstrate ~68% complete tumor response rate (36% with DSA alone)14
Needle ASSIST8 provides real-time visualization of needle positions in the 3D space. It can help medical professionals improve their accuracy, reduce dose and support efficiency efforts when performing needle interventions, while having a limited impact on workflow.
INTERACT Active Tracker enables easy and automatic fusion between ultrasound and multiple modalities’ pre-operative images right within the interventional suite.
Bringing ultrasound in the angio suite allows to overcome the main limitations associated with CT-guidance in percutaneous procedures while offering incremental benefit of live multi-modality fusion guidance.
1. Kwan, S. W., Kerlan, R. K., & Sunshine, J. H. (2010). Utilization of Interventional Oncology Treatments in the United States. Journal of Vascular and Interventional Radiology: JVIR, 21(7), 1054–1060. https://doi.org/10.1016/j.jvir.2010.02.028
2. https://pubs.rsna.org/doi/pdf/10.1148/radiol.14131925
3. Discovery IGS 7 is not available in all markets. Refer to your sales representative.
4. Motion Freeze may not be available in all markets. Refer to your sales representative. The improvement related to Motion Freeze depends on the acquisition conditions, table position, patient, type of motion, anatomical location and clinical practice. Motion Freeze is an optional feature of 3DXR (part of GE Interventional systems Innova IGS 5, Innova IGS 6 and Discovery IGS 7 or Discovery IGS 7OR). 3DXR may not be available in all markets. Refer to your sales representative.
4a. Based on competitive research, among major players in interventional imaging.
5. Liver ASSIST solution includes Hepatic VCAR and FlightPlan for Liver that can be used independently. It also requires an AW workstation with Volume Viewer and Volume Viewer Innova. These applications are sold separately.
6. INTERACT Active Tracker is an optional feature of 3DXR (part of GE Interventional systems Innova IGS 5, Innova IGS 6 and Discovery IGS 7 or Discovery IGS 7OR). This feature supports only one ‘Active Tracker’ type: the OmniTRAX™ Active Patient Tracker of CIVCO™. 3DXR and INTERACT Active Tracker may not be available in all markets. Refer to your sales representative.
7. Requires availability of a LOGIQ E9 or LOGIQ E10 system with XDclear (sold separately).
8. Needle ASSIST solution includes TrackVision 2, Stereo 3D and requires AW workstation with Volume Viewer, Volume Viewer Innova. These applications are sold separately.
9. Established from health Organization databases publicly available. World’s Health Organization data “Global Database on Body Mass Index” and World’s Health Organization: “Obesity and overweight Fact sheet N°311 Updated January 2015” and “CDC/NCHS 2007-2008 National Health and Nutrition examination survey and 2007 – 2009 Canadian Health measures survey."
10. Based on the quantitative assessment of 6 recognized Interventional Radiologists specialized in the field of Interventional Oncology, using various intervention angiography systems from different vendors.
11. Computed Analysis of Three-Dimensional Cone-Beam Computed Tomography Angiography for Determination of Tumor-Feeding Vessels During Chemoembolization of Liver Tumor: A Pilot Study – Deschamps et al. Cardiovasc Intervent Radiol. 2010.
12. Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using Three-Dimensional Cone-Beam CT Angiography – Minami et al. Liver Cancer. 2014.
13. Clinical utility and limitations of tumor-feeder detection software for liver cancer embolization. Iwazawa et al. European Journal of Radiology. 2013. For additional information please visit: https://www3.gehealthcare.com/en/products/categories/interventional_image_guided_systems/assist/flight_plan_for_liver
14. Cornelis, F.H., Borgheresi, A., Petre, E.N., Santos, E., Solomon, S.B., and Brown, K. (2017). Hepatic Arterial Embolization Using Cone Beam CT with Tumor Feeding Vessel Detection Software: Impact on Hepatocellular Carcinoma Response. Cardiovasc. Intervent. Radiol.